Deflazacort Oral Suspension
22.75 mg/mL · Suspension
- Prescription only
- Corticosteroid
- Active substance
- Deflazacort
- Made by
- Zydus Pharmaceuticals (USA) Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (JAYTHARI Oral Suspension). It describes the substance, not this exact product.
Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects.
The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.
Deflazacort is rapidly converted to the active metabolite 21-desDFZ by esterases after oral administration. 21-desDFZ is further metabolized by CYP3A4 to several other inactive metabolites, including 6β-hydroxy-21-desacetyl deflazacort.
Urinary excretion is the predominant route of deflazacort elimination (about 68% of the dose), and the elimination is almost completed by 24 hours post dose. 21-desDFZ accounts for 18% of the eliminated drug in the urine.
Food Effect: Co-administration of deflazacort tablets with a high-fat meal reduced C max by about 30% and delayed T max by one hour, relative to administration under fasting conditions, but there was no effect on the overall systemic absorption as measured by AUC.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-10
Safety of the active substance
From the US prescribing label for the same active substance (JAYTHARI Oral Suspension). It describes the substance, not this exact product.
- JAYTHARI is contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients.
- Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy [see Warnings and Precautions (5.15) and Adverse Reactions (6.2) ].
- Hypersensitivity to deflazacort or any of the inactive ingredients in JAYTHARI ( 4 )
Most Common Adverse Reactions in Clinical Studies Table 1 lists the adverse reactions that occurred in ≥5% of patients in the 0.9 mg/kg/day deflazacort-treated group and that occurred more frequently than in placebo patients in Study 1, which included patients with DMD between the ages of 5 and 15 years.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | Zydus Pharmaceuticals (USA) Inc. |
|---|---|
| Active substance | Deflazacort |
| Used in | Hormones, such as thyroid and steroids |
| Strength | 22.75 mg/mL |
| Form | Suspension |
| Route | Oral |
| Packs | 1 BOTTLE in 1 CARTON / 13 mL in 1 BOTTLE |
| NDC | 70710-2007 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Suspension4 products
22.75 mg/mL4
22.75 mg/mL · 4 companies
- Cranbury Pharmaceuticals, LLC
- Doppel Farmaceutici S.r.l.
- Sun Pharmaceutical Industries, Inc.
- Zydus Pharmaceuticals (USA) Inc. · this page
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.